Novartis BP drug sees approval in Europe

Share this article:
The European Commission approved Novartis' Rasilez (aliskiren) for use in the European Union.

The approval follows an FDA endorsement earlier this year in the US, where the drug is sold as Tekturna. It's also approved in Switzerland.

Analysts have estimated peak sales of between $2.5 billion to $3.5 billion for the Novartis pill, which was co-developed by Swiss biotech company Speedel.

When used alone, Rasilez demonstrates greater blood pressure lowering than other commonly-used blood pressure medicines, like ACE inhibitors and certain diuretics. When added to existing therapy, it provides additional blood pressure lowering, the company said in a statement.

Novartis said nearly a billion people around the world have high blood pressure, and almost 70% do not reach their blood pressure goal.

Tekturna targets renin, an enzyme responsible for triggering a process that can contribute to the condition.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.